Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III adjuvant osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer
MOH_2017-06-18_000429Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Oct 2015; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2017-06-18_000429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-18_000429.